10-K: Family Office of America Reports FY24 Results, Navigates Transition and Seeks Growth

Family Office of America, formerly Qualis Innovations, reports its FY24 results, highlighting a name change, ongoing development of its SOLACE device, and efforts to secure additional capital amid going concern uncertainties.

Summary

• Family Office of America, Inc., formerly Qualis Innovations, reported its financial results for the year ended December 31, 2024.
• The company changed its name from Qualis Innovations, Inc. to Family Office of America, Inc. on December 17, 2024.
• The company is focused on developing, producing, and distributing pain management and other central nervous system (CNS) based solutions.
• The company is developing SOLACE, a non-invasive medical device for pain relief, but has not yet finalized its development or generated any cash flows from it.
• The company recorded an impairment of assets totaling $76,008 in 2023 due to the inability of a third-party manufacturer to deliver SOLACE devices.
• The company initiated a Regulation D offering on January 15, 2025, to sell up to 6,000,000 common shares at $0.10 per share, raising $275,000 as of March 7, 2025.
• The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.
• The company had a net loss of $100,484 for the year ended December 31, 2024, compared to a net loss of $805,021 for the year ended December 31, 2023.
• The company had no revenues for the years ended December 31, 2024 and 2023.
• The company's operating expenses decreased by 58.1% to $96,513 for the year ended December 31, 2024.
• The company had an accumulated deficit of $4,530,792 as of December 31, 2024.
• The company's independent auditors have issued a report that includes an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative due to the company's going concern uncertainties, lack of revenue, and accumulated losses. However, the decrease in operating expenses and ongoing efforts to raise capital provide some hope for the future.

Positives

• Operating expenses decreased by $133,728, or 58.1%, to $96,513 for year ended December 31, 2024 from $230,241 for the year ended December 31, 2023.
• The company is actively seeking additional capital through a Regulation D offering.
• The company is developing a product, SOLACE, designed to address unmet needs in pain management.

Negatives

• The company has a limited operating history and has not generated any cash flow from operations.
• The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.
• The company had a net loss of $100,484 for the year ended December 31, 2024, and $805,021 for the year ended December 31, 2023.
• The company recorded an impairment of assets totaling $76,008 in 2023 due to manufacturing issues with the SOLACE device.
• The company had an accumulated deficit of $4,530,792 as of December 31, 2024.
• The company's cash position may not be sufficient to support daily operations.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital and generate revenues.
• The company faces intense competition in the medical device industry.
• The company's planned SOLACE device is subject to FDA approval, and failure to obtain approval could have a material adverse effect on the business.
• The company is subject to extensive regulation by the FDA and foreign and state regulatory authorities.
• The company relies on third-party manufacturers, which could lead to supply chain disruptions.
• The company may not be successful in preventing or mitigating a cybersecurity incident.

Future Outlook

The company intends to raise additional funds by way of a public offering or an asset sale transaction to support its operations and growth.

Industry Context

The company operates in the competitive medical device industry, where innovation and regulatory approvals are critical for success. The company is focused on pain management solutions, an area with significant unmet needs and growing demand for non-traditional therapies.

Comparison to Industry Standards

• Given the company's stage of development and lack of revenue, it is difficult to directly compare it to established industry players.
• Companies like Boston Scientific, Medtronic, and Abbott have significant resources and established product portfolios, while Family Office of America is focused on developing and commercializing a single product.
• Other smaller companies in the pain management space, such as Nevro and Stimwave, have achieved commercial success with innovative neuromodulation technologies, but they also required significant capital investment and regulatory approvals.
• The company's success will depend on its ability to secure funding, obtain regulatory clearance for its SOLACE device, and effectively market its product to a target audience of professionals specializing in multi-modal pain management techniques.

Management Changes

Related Party Transactions

• The company borrows funds from the Company's CEO for working capital purposes from time to time.
• In January 2024, the Company issued 2,000,000 common shares to two (2) affiliates for aggregate gross proceeds of $100,000.
• In January 2024, the Company issued a total of 10,000,000 common shares valued at $500,000 (based on the estimated fair value of the stock on the date of grant) to two affiliates in settlement of a dispute.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainties and lack of revenue.
• Employees are impacted by the company's limited resources and potential need for cost-cutting measures.
• Customers may benefit from the development of the SOLACE device, but its availability is uncertain.
• Suppliers face potential risk due to the company's financial instability.
• Creditors face potential risk due to the company's going concern uncertainties.

Next Steps

• Finalize development of the SOLACE device.
• Obtain FDA approval for the SOLACE device.
• Secure additional capital through a public offering or asset sale transaction.
• Expand operations to provide business management and financial consulting services to accounting firms throughout the United States.

Key Dates

Keywords

Family Office of America, SOLACE, mPathix, pain management, medical device, Regulation D, going concern, financial results, impairment, warrants